Abstract:New drugs to protect or mitigate total body irradiation (TBI) damage are urgently required. To determine whether existing pharmacologic agents have this second function, we used siRNA to screen 5,520 druggable targets in the Silencer Druggable Genome siRNA library (Version 1.1, Ambion, Austin, TX). We sought to identify genes which if silenced protected against or mitigated radiation damage. T98G human glioblastoma cells were transfected with each target in the siRNA library in triplicate at a final concentration of 20nM/target in a one-gene, one-well format using DharmaFECT2 transfection reagent and 48 hours later were irradiated to 25 Gy. Viability was measured 72 hours later using the CellTiter-Blue cell viability assay. The siRNA screen was performed three times and a hit was scored as a gene, which when silenced, protected T98G cells by at least 15% in each of the triplicate screens. We identified 117 candidate protective genes. These were further analyzed using Ingenuity Pathways Analysis to identify potential radiation inhibitor signaling pathways and drug candidates. One pharmacologically attractive candidate was glybenclamide. Glybenclamide is a sulfonylurea currently used to treat diabetes that inhibits the ATP-binding cassette, sub-family A (ABC1) and selectively blocks ATP sensitive potassium channels. Glybenclamide (10 μM) was added to 32D cl 3 murine hematopoietic progenitor cells one hour before irradiation, or immediately following irradiation. Cells were then irradiated to doses ranging from 0 to 8 Gy, plated in methylcellulose, and incubated for seven days at 37° C in a humidified CO2 incubator at which time colonies of greater than 50 cells were counted. The data were analyzed using linear quadratic or single-hit, multi-target models. Glybenclamide pre-irradiation treated cells were protected from irradiation as demonstrated by an increased shoulder on the survival curve with a n of 34.9 ± 0.5 compared to untreated 32D cl 3 cells or cells treated with glybenclamide after irradiation with a n of 3.1 ± 1.3 or 2.5 ± 0.9 (p = 0.0018 or < 0.0001, respectively). To determine if glybenclamide was radioprotective in vivo, we dissolved the drug in 50% Cremophor EL and 50% ethanol and then diluted 1:4 in water. C57BL/6NHsd female mice were injected intraperitoneally with 5 mg/kg glybenclamide either 10 minutes before or 10 minutes after TBI to the LD50/30 dose of 9.5 Gy. Duplicate groups received sucrose supplement to counteract potential hypoglycemia. We found that 60% of mice injected with glybenclamide before irradiation survived for 35 days compared to 33% for the TBI alone group (p = 0.0361), while 44% of mice injected with glybenclamide following irradiation survived. There was no significant effect of sucrose supplement or difference between irradiated controls, mice injected with vehicle only or glybenclamide following irradiation. These results demonstrate the power of unbiased siRNA screening with a druggable genome and suggest that glybenclamide might be a clinically useful radioprotector.

Borane-protected phosphines are redox-active radioprotective agents for endothelial cells

Intracellular disulfide reduction by phosphine-borane complexes: Mechanism of action for neuroprotection

Effectiveness of Novel Borane-Phosphine Complexes In Inhibiting Cell Death Depends on the Source of Superoxide Production Induced by Blockade of Mitochondrial Electron Transport

Oxidant-Dependent Sensitizing, Protective, and Mitigative Effects in X-Ray-Irradiated Pulmonary Endothelial Cells

Synthesis and radioprotective effects of novel hybrid compounds containing edaravone analogue and 3-n-butylphthalide ring-opening derivatives

Phosphatidylinositol 3 Kinase/Protein Kinase B is Responsible for the Protection of Paeoniflorin Upon H2o2-Induced Neural Progenitor Cell Injury

Reactive Oxygen Species-Responsive Nanodrug of Natural Crocin-I with Prolonged Circulation for Effective Radioprotection

Effect of boron compounds on the biological effectiveness of proton therapy

Antioxidants Hydroxytyrosol and Thioredoxin-Mimetic Peptide CB3 Protect Irradiated Normal Tissue Cells

Redox-responsive nanoparticles enhance radiation therapy by altering multifaceted radio-resistance mechanisms in human castration-resistant prostate cancer cells and xenografts

Protective role of alpha-phenyl-N-t-butylnitrone against ionizing radiation in U937 cells and mice

Boric Acid and Borax Protect Human Lymphocytes from Oxidative Stress and Genotoxicity Induced by 3-Monochloropropane-1,2-diol

Bone Marrow Small Molecule Radioprotectors.

Design, Synthesis, and Biological Evaluation of a Novel Aminothiol Compound As Potential Radioprotector

Impact of the redox environment on propagation of radiation bystander effects: The modulating effect of oxidative metabolism and oxygen partial pressure

Druggable Genome Sirna-Screening Identifies Glybenclamide As A Radioprotector Against Total Body Irradiation

β-D-Glucan promotes NF-κB activation and ameliorates high-LET carbon-ion irradiation-induced human umbilical vein endothelial cell injury

Protective effect of propolis in protecting against radiation-induced oxidative stress in the liver as a distant organ

RRx-001 Radioprotection: Enhancement of Survival and Hematopoietic Recovery in Gamma-Irradiated Mice

Effect of a bradykinin-potentiating factor isolated from scorpion venom (Leiurus quinquestriatus) on some blood indices and lipid profile in irradiated rats

Impact of the PrC-210 Radioprotector Molecule on Cancer Deaths in p53-Deficient Mice